Ablynx's trial of aTTP treatment caplacizumab shows positive results
Belgian company Ablynx has reported positive topline results from the Phase III HERCULES trial with caplacizumab to treat acquired thrombotic thrombocytopenic purpura (aTTP).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Belgium Health | Pharmaceuticals